Lenalidomide

Overdose

There is no specific experience in the management of lenalidomide overdose in patients, although in dose- ranging studies some patients were exposed to up to 150 mg, and in single-dose studies, some patients were exposed to up to 400 mg. The dose limiting toxicity in these studies was essentially haematological. In the event of overdose, supportive care is advised.

Contraindications

-

- Women who are pregnant.

- Women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme are met.

Incompatibilities

Not applicable.

Pharmaceutical form

Capsules; Substance-powder

Undesirable effects

Summary of the safety profile Newly diagnosed multiple myeloma: patients who have undergone ASCT treated with lenalidomide maintenance

A conservative approach was applied to determine the adverse reactions from CALGB 100104. The adverse reactions described in Table 1 included events reported post-HDM/ASCT as well as events from the maintenance treatment period. A second analysis that identified events that occurred after the start of maintenance treatment suggests that the frequencies described in Table 1 may be higher than actually observed during the maintenance treatment period. In IFM 2005-02, the adverse reactions were from the maintenance treatment period only.

The serious adverse reactions observed more frequently (>5%) with lenalidomide maintenance than placebo were:

- Pneumonias (10.6%; combined term) from IFM 2005-02

- Lung infection (9.4% [9.4% after the start of maintenance treatment]) from CALGB 100104

In the IFM 2005-02 study, the adverse reactions observed more frequently with lenalidomide maintenance than placebo were neutropenia (60.8%), bronchitis (47.4%), diarrhoea (38.9%), nasopharyngitis (34.8%), muscle spasms (33.4%), leucopenia (31.7%), asthenia (29.7%), cough (27.3%), thrombocytopenia (23.5%), gastroenteritis (22.5%) and pyrexia (20.5%).

In the CALGB 100104 study, the adverse reactions observed more frequently with lenalidomide maintenance than placebo were neutropenia (79.0% [71.9% after the start of maintenance treatment]), thrombocytopenia (72.3% [61.6%]), diarrhoea (54.5% [46.4%]), rash (31.7% [25.0%]), upper respiratory tract infection (26.8% [26.8%]), fatigue (22.8% [17.9%]), leucopenia (22.8% [18.8%]) and anemia (21.0% [13.8%]).

Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with low dose dexamethasone

The serious adverse reactions observed more frequently (>5%) with lenalidomide in combination with low dose dexamethasone (Rd and Rd18) than with melphalan, prednisone and thalidomide (MPT) were:

- Pneumonia (9.8%)

- Renal failure (including acute) (6.3%)

The adverse reactions observed more frequently with Rd or Rd18 than MPT were: diarrhoea (45.5%), fatigue (32.8%), back pain (32.0%), asthenia (28.2%), insomnia (27.6%), rash (24.3%), decreased appetite (23.1%), cough (22.7%), pyrexia (21.4%), and muscle spasms (20.5%).

Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with melphalan and prednisone

The serious adverse reactions observed more frequently (>5%) with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance (MPR+R) or melphalan, prednisone and lenalidomide followed by placebo (MPR+p) than melphalan, prednisone and placebo followed by placebo (MPp+p) were:

- Febrile neutropenia (6.0%)

- Anemia (5.3%)

The adverse reactions observed more frequently with MPR+R or MPR+p than MPp+p were: neutropenia (83.3%), anemia (70.7%), thrombocytopenia (70.0%), leukopenia (38.8%), constipation (34.0%), diarrhoea (33.3%), rash (28.9%), pyrexia (27.0%), peripheral oedema (25.0%), cough (24.0%), decreased appetite (23.7%), and asthenia (22.0%).

Multiple myeloma: patients with at least one prior therapy

In two phase III placebo-controlled studies, 353 patients with multiple myeloma were exposed to the lenalidomide/dexamethasone combination and 351 to the placebo/dexamethasone combination.

The most serious adverse reactions observed more frequently in lenalidomide/dexamethasone than placebo/dexamethasone combination were:

- Venous thromboembolism (deep vein thrombosis, pulmonary embolism)

- Grade 4 neutropenia.

The observed adverse reactions which occurred more frequently with lenalidomide and dexamethasone than placebo and dexamethasone in pooled multiple myeloma clinical trials (MM-009 and MM-010) were fatigue (43.9%), neutropenia (42.2%), constipation (40.5%), diarrhoea (38.5%), muscle cramp (33.4%), anemia (31.4%), thrombocytopenia (21.5%), and rash (21.2%).

Myelodysplastic syndromes

The overall safety profile of lenalidomide in patients with myelodysplastic syndromes is based on data from a total of 286 patients from one phase II study and one phase III study. In the phase II, all 148 patients were on lenalidomide treatment. In the phase III study, 69 patients were on lenalidomide 5 mg, 69 patients on lenalidomide 10 mg and 67 patients were on placebo during the double-blind phase of the study.

Most adverse reactions tended to occur during the first 16 weeks of therapy with lenalidomide.

Serious adverse reactions include:

- Venous thromboembolism (deep vein thrombosis, pulmonary embolism)

- Grade 3 or 4 neutropenia, febrile neutropenia and grade 3 or 4 thrombocytopenia.

The most commonly observed adverse reactions which occurred more frequently in the lenalidomide groups compared to the control arm in the phase III study were neutropenia (76.8%), thrombocytopenia (46.4%), diarrhoea (34.8%), constipation (19.6%), nausea (19.6%), pruritus (25.4%), rash (18.1%), fatigue (18.1%) and muscle spasms (16.7%).

Mantle cell lymphoma

The overall safety profile of lenalidomide in patients with mantle cell lymphoma is based on data from 254 patients from a phase II randomised, controlled study MCL-002.

Additionally, adverse drug reactions from supportive study MCL-001 have been included in table 3.

The serious adverse reactions observed more frequently in study MCL-002 (with a difference of at least 2 percentage points) in the lenalidomide arm compared with the control arm were:

- Neutropenia (3.6%)

- Pulmonary embolism (3.6%)

- Diarrhoea (3.6%)

The most frequently observed adverse reactions which occurred more frequently in the lenalidomide arm compared with the control arm in study MCL-002 were neutropenia (50.9%), anemia (28.7%), diarrhoea (22.8%), fatigue (21.0%), constipation (17.4%), pyrexia (16.8%), and rash (including dermatitis allergic) (16.2%).

In study MCL-002 there was overall an apparent increase in early (within 20 weeks) deaths. Patients with high tumour burden at baseline are at increased risk of early death, 16/81 (20%) early deaths in the lenalidomide arm and 2/28 (7%) early deaths in the control arm. Within 52 weeks corresponding figures were 32/81 (39.5%) and 6/28 (21%).

During treatment cycle 1, 11/81 (14%) patients with high tumour burden were withdrawn from therapy in the lenalidomide arm vs. 1/28 (4%) in the control group. The main reason for treatment withdrawal for patients with high tumour burden during treatment cycle 1 in the lenalidomide arm was adverse events, 7/11 (64%). High tumour burden was defined as at least one lesion >5 cm in diameter or 3 lesions >3 cm.

Tabulated list of adverse reactions

The adverse reactions observed in patients treated with lenalidomide are listed below by system organ class and frequency. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequencies are defined as: very common (> 1/10); common (> 1/100 to < 1/10); uncommon (> 1/1,000 to < 1/100); rare (> 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).

Adverse reactions have been included under the appropriate category in the table below according to the highest frequency observed in any of the main clinical trials.

Tabulated summary for monotherapy in MM

The following table is derived from data gathered during NDMM studies in patients who have undergone ASCT treated with lenalidomide maintenance. The data were not adjusted according to the longer duration of treatment in the lenalidomide-containing arms continued until disease progression versus the placebo arms in the pivotal multiple myeloma studies.

Table 1. ADRs reported in clinical trials in patients with multiple myeloma treated with lenalidomide maintenance therapy

System Organ Class/Preferred Term

All ADRs/Frequency

Grade 3-4 ADRs/Frequency

Infections and Infestations

Very Common

Pneumoniasâ—Š, a, Upper respiratory tract infection, Neutropenic infection, Bronchitisâ—Š, Influenzaâ—Š, Gastroenteritisâ—Š, Sinusitis, Nasopharyngitis, Rhinitis

Common

Infectionâ—Š, Urinary tract infectionâ—Š*, Lower respiratory tract infection, Lung infection

Very Common

Pneumoniasâ—Š, a, Neutropenic infection

Common

Sepsisâ—Š, b, Bacteraemia, Lung infectionâ—Š, Lower respiratory tract infection bacterial, Bronchitisâ—Š, Influenzaâ—Š, Gastroenteritisâ—Š, Herpes zosterâ—Š, Infectionâ—Š

Neoplasms Benign, Malignant and Unspecified (incl cysts and polyps)

Common

Myelodysplastic syndromeâ—Š*

Blood and Lymphatic System Disorders

Very Common

Neutropenia^,â—Š, Febrile neutropenia^,â—Š, Thrombocytopenia^,â—Š,, Anemia, Leucopeniaâ—Š, Lymphopenia

Very Common

Neutropenia^,â—Š, Febrile neutropenia^,â—Š, Thrombocytopenia^,â—Š, Anemia, Leucopeniaâ—Š, Lymphopenia

Common

Pancytopeniaâ—Š

Metabolism and Nutrition Disorders

Very Common

Hypokalaemia

Common

Hypokalaemia, Dehydration

Nervous System Disorders

Very Common

Paraesthesia

Common

Peripheral neuropathyc

Common

Headache

Vascular Disorders

Common

Pulmonary embolismâ—Š*

Common

Deep vein thrombosis^,â—Š,d

Respiratory, Thoracic and Mediastinal Disorders

Very Common

Cough

Common

Dyspnoeaâ—Š, Rhinorrhoea

Common

Dyspnoeaâ—Š

Gastrointestinal Disorders

Very Common

Diarrhoea, Constipation, Abdominal pain, Nausea

Common

Vomiting, Abdominal pain upper

Common

Diarrhoea, Vomiting, Nausea

Hepatobiliary Disorders

Very Common

Abnormal liver function tests

Common

Abnormal liver function tests

Skin and Subcutaneous Tissue Disorders

Very Common

Rash, Dry skin

Common

Rash, Pruritus

Musculoskeletal and Connective Tissue Disorders

Very Common

Muscle spasms

Common

Myalgia, Musculoskeletal pain

General Disorders and Administration Site Conditions

Very Common

Fatigue, Asthenia, Pyrexia

Common

Fatigue, Asthenia

â—Š Adverse reactions reported as serious in clinical trials in patients with NDMM who had undergone ASCT

* Applies to serious adverse drug reactions only

^

a “Pneumonias” combined AE term includes the following PTs: Bronchopneumonia, Lobar pneumonia, Pneumocystis jiroveci pneumonia, Pneumonia, Pneumonia klebsiella, Pneumonia legionella, Pneumonia mycoplasmal, Pneumonia pneumococcal, Pneumonia streptococcal, Pneumonia viral, Lung disorder, Pneumonitis

b “Sepsis” combined AE term includes the following PTs: Bacterial sepsis, Pneumococcal sepsis, Septic shock, Staphylococcal sepsis

c “Peripheral neuropathy” combined AE term includes the following preferred terms (PTs): Neuropathy peripheral, Peripheral sensory neuropathy, Polyneuropathy

d “Deep vein thrombosis” combined AE term includes the following PTs: Deep vein thrombosis, Thrombosis, Venous thrombosis

Tabulated summary for combination therapy in MM

The following table is derived from data gathered during the multiple myeloma studies with combination therapy. The data were not adjusted according to the longer duration of treatment in the lenalidomide-containing arms continued until disease progression versus the comparator arms in the pivotal multiple myeloma studies.

Table 2. ADRs reported in clinical studies in patients with multiple myeloma treated with lenalidomide in combination with dexamethasone, or with melphalan and prednisone

System Organ Class / Preferred Term

All ADRs/Frequency

Grade 3−4 ADRs/Frequency

Infections and Infestations

Very Common

Pneumonia, Upper respiratory tract infection, Bacterial, viral and fungal infections (including opportunistic infections), Nasopharyngitis, Pharyngitis, Bronchitis

Common

Sepsis, Sinusitis

Common

Pneumonia, Bacterial, viral and fungal infections (including opportunistic infections), Sepsis, Bronchitis

Neoplasms Benign, Malignant and Unspecified (incl cysts and polyps)

Uncommon

Basal cell carcinoma, Squamous skin cancer^*

Common

Acute myeloid leukaemia, Myelodysplastic syndrome, Squamous cell carcinoma of skin**

Uncommon

T-cell type acute leukaemia, Basal cell carcinoma, Tumour lysis syndrome

Blood and Lymphatic System Disorders

Very Common

Neutropenia^, Thrombocytopenia ^, Anemia, Haemorrhagic disorder ^, Leucopenias

Common

Febrile neutropenia, Pancytopenia

Uncommon

Haemolysis, Autoimmune haemolytic anemia, Haemolytic anemia

Very Common

Neutropenia^, Thrombocytopenia^, Anemia, Leucopenias

Common

Febrile neutropenia^, Pancytopenia, Haemolytic anemia

Uncommon

Hypercoagulation, Coagulopathy

Immune System Disorders

Uncommon

Hypersensitivity^

Endocrine Disorders

Common

Hypothyroidism

Metabolism and Nutrition Disorders

Very Common

Hypokalaemia, Hyperglycaemia, Hypocalcaemia, Decreased appetite, Weight decreased

Common

Hypomagnesaemia, Hyperuricaemia, Dehydration

Common

Hypokalaemia, Hyperglycaemia, Hypocalcaemia, Diabetes mellitus, Hypophosphataemia, Hyponatraemia, Hyperuricaemia, Gout, Decreased appetite, Weight decreased

Psychiatric Disorders

Very Common

Depression, Insomnia

Uncommon

Loss of libido

Common

Depression, Insomnia

Nervous System Disorders

Very Common

Peripheral neuropathies (excluding motor neuropathy), Dizziness, Tremor, Dysgeusia, Headache

Common

Ataxia, Balance impaired

Common

Cerebrovascular accident, Dizziness, Syncope

Uncommon

Intracranial haemorrhage ^, Transient ischaemic attack, Cerebral ischaemia

Eye Disorders

Very Common

Cataracts, Blurred vision

Common

Reduced visual acuity

Common

Cataract

Uncommon

Blindness

Ear and Labyrinth Disorders

Common

Deafness (Including Hypoacusis), Tinnitus

Cardiac Disorders

Common

Atrial fibrillation, Bradycardia

Uncommon

Arrhythmia, QT prolongation, Atrial flutter, Ventricular extrasystoles

Common

Myocardial infarction (including acute)^, Atrial fibrillation, Congestive cardiac failure, Tachycardia, Cardiac failure, Myocardial ischaemia

Vascular Disorders

Very Common

Venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism^

Common

Hypotension, Hypertension, Ecchymosis^

Very Common

Venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism^

Common

Vasculitis

Uncommon

Ischemia, Peripheral ischemia, Intracranial venous sinus thrombosis

Respiratory, Thoracic and Mediastinal Disorders

Very Common

Dyspnoea, Epistaxis^

Common

Respiratory distress, Dyspnoea

Gastrointestinal Disorders

Very Common

Diarrhoea, Constipation, Abdominal pain, Nausea, Vomiting, Dyspepsia

Common

Gastrointestinal haemorrhage (including rectal haemorrhage, haemorrhoidal haemorrhage, peptic ulcer haemorrhage and gingival bleeding)^, Dry mouth, Stomatitis, Dysphagia

Uncommon

Colitis, Caecitis

Common

Diarrhoea, Constipation, Abdominal pain, Nausea, Vomiting

Hepatobiliary Disorders

Common

Abnormal liver function tests

Uncommon

Hepatic failure^

Common

Cholestasis, Abnormal liver function tests

Uncommon

Hepatic failure^

Skin and Subcutaneous Tissue Disorders

Very Common

Rashes, Pruritus

Common

Urticaria, Hyperhidrosis, Dry skin, Skin hyperpigmentation, Eczema, Erythema

Uncommon

Skin discolouration, Photosensitivity reaction

Common

Rashes

Musculoskeletal and Connective Tissue Disorders

Very Common

Muscle spasms, Bone pain, Musculoskeletal and connective tissue pain and discomfort, Arthralgia

Common

Muscular weakness, Joint swelling, Myalgia

Common

Muscular weakness, Bone pain

Uncommon

Joint swelling

Renal and Urinary Disorders

Very Common

Renal failure (including acute)

Common

Haematuria^, Urinary retention, Urinary incontinence

Uncommon

Acquired Fanconi syndrome

Uncommon

Renal tubular necrosis

Reproductive System and Breast Disorders

Common

Erectile dysfunction

General Disorders and Administration Site Conditions

Very Common

Fatigue, Oedema (including peripheral oedema), Pyrexia, Asthenia, Influenza like illness syndrome (including pyrexia, cough, myalgia, musculoskeletal pain, headache and rigors)

Common

Chest pain, Lethargy

Common

Fatigue, Pyrexia, Asthenia

Investigations

Common

C-reactive protein increased

Injury, Poisoning and Procedural Complications

Common

Fall, Contusion^

^

* Squamous skin cancer was reported in clinical trials in previously treated myeloma patients with lenalidomide/dexamethasone compared to controls

** Squamous cell carcinoma of skin was reported in a clinical trial in newly diagnosed myeloma patients with lenalidomide/dexamethasone compared to controls

Tabulated summary from monotherapy

The following table are derived from data gathered during the main studies in monotherapy for myelodysplastic syndromes and mantle cell lymphoma.

Table 3. ADRs reported in clinical trials in patients with myelodysplastic syndromes treated with lenalidomide#

System Organ Class / Preferred Term

All ADRs/Frequency

Grade 3−4 ADRs/Frequency

Infections and Infestations

Very Common

Bacterial, viral and fungal infections (including opportunistic infections)

Very Common

Pneumoniaâ—Š

Common

Bacterial, viral and fungal infections (including opportunistic infections) â—Š, Bronchitis

Blood and Lymphatic System Disorders

Very Common

Thrombocytopenia^, Neutropenia^, Leucopenias

Very Common

Thrombocytopenia^â—Š, Neutropenia^â—Š, Leucopenias

Common

Febrile neutropenia^â—Š

Endocrine Disorders

Very Common

Hypothyroidism

Metabolism and Nutrition Disorders

Very Common

Decreased appetite

Common

Iron overload, Weight decreased

Common

Hyperglycaemiaâ—Š, Decreased appetite

Psychiatric Disorders

Common

Altered moodâ—Š~

Nervous System Disorders

Very Common

Dizziness, Headache

Common

Paraesthesia

Cardiac Disorders

Common

Acute myocardial infarction^â—Š, Atrial fibrillationâ—Š, Cardiac failureâ—Š

Vascular Disorders

Common

Hypertension, Haematoma

Common

Venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism^â—Š

Respiratory, Thoracic and Mediastinal Disorders

Very Common

Epistaxis^

Gastrointestinal Disorders

Very Common

Diarrhoea, Abdominal pain (including upper), Nausea, Vomiting, Constipation

Common

Dry mouth, Dyspepsia

Common

Diarrhoeaâ—Š, Nausea, Toothache

Hepatobiliary Disorders

Common

Abnormal liver function tests

Common

Abnormal liver function tests

Skin and Subcutaneous Tissue Disorders

Very Common

Rashes, Dry Skin, Pruritus

Common

Rashes, Pruritus

Musculoskeletal and Connective Tissue Disorders

Very Common

Muscle spasms, Musculoskeletal pain (including back pain and pain in extremity), Arthralgia, Myalgia

Common

Back painâ—Š

Renal and Urinary Disorders

Common

Renal failureâ—Š

General Disorders and Administration Site Conditions

Very Common

Fatigue, Peripheral oedema, Influenza like illness syndrome (including pyrexia, cough, pharyngitis, myalgia, musculoskeletal pain, headache)

Common

Pyrexia

Injury, Poisoning and Procedural Complications

Common

Fall

^see section 4.8 description of selected adverse reactions

â—ŠAdverse events reported as serious in myelodysplastic syndromes clinical trials

~Altered mood was reported as a common serious adverse event in the myelodysplastic syndromes phase III study; it was not reported as a grade 3 or 4 adverse event

Algorithm applied for inclusion in the SmPC: All ADRs captured by the phase III study algorithm are included in the EU SmPC. For these ADRs, an additional check of the frequency of the ADRs captured by the phase II study algorithm was undertaken and, if the frequency of the ADRs in the phase II study was higher than in the phase III study, the event was included in the EU SmPC at the frequency it occurred in the phase II study.

# Algorithm applied for myelodysplastic syndromes:

- Myelodysplastic syndromes phase III study (double-blind safety population, difference between lenalidomide 5/10mg and placebo by initial dosing regimen occurring in at least 2 subjects)

o All treatment-emergent adverse events with > 5% of subjects in lenalidomide and at least 2% difference in proportion between lenalidomide and placebo

o All treatment-emergent grade 3 or 4 adverse events in 1% of subjects in lenalidomide and at least 1% difference in proportion between lenalidomide and placebo

o All treatment-emergent serious adverse events in 1% of subjects in lenalidomide and at least 1% difference in proportion between lenalidomide and placebo

- Myelodysplastic syndromes phase II study

o All treatment-emergent adverse events with > 5% of lenalidomide treated subjects

o All treatment-emergent grade 3 or 4 adverse\events in 1% of lenalidomide treated subjects

o All treatment-emergent serious adverse events in 1% of lenalidomide treated subjects

Table 4. ADRs reported in clinical trials in patients with mantle cell lymphoma treated with lenalidomide

System Organ Class / Preferred Term

All ADRs/Frequency

Grade 3−4 ADRs/Frequency

Infections and Infestations

Very Common

Bacterial, viral and fungal infections (including opportunistic infections), Nasopharyngitis, Pn

Preclinical safety data

An embryofoetal development study has been conducted in monkeys administered lenalidomide at doses from 0.5 and up to 4 mg/kg/day. Findings from this study indicate that lenalidomide produced external malformations including non-patent anus and malformations of upper and lower extremities (bent, shortened, malformed, malrotated and/or absent part of the extremities, oligo and/or polydactyly) in the offspring of female monkeys who received the active substance during pregnancy.

Various visceral effects (discoloration, red foci at different organs, small colourless mass above atrio- ventricular valve, small gall bladder, malformed diaphragm) were also observed in single foetuses.

Lenalidomide has a potential for acute toxicity; minimum lethal doses after oral administration were > 2000 mg/kg/day in rodents. Repeated oral administration of 75, 150 and 300 mg/kg/day to rats for up to 26 weeks produced a reversible treatment-related increase in kidney pelvis mineralisation in all 3 doses, most notably in females. The no observed adverse effect level (NOAEL) was considered to be less than 75 mg/kg/day, and is approximately 25-fold greater than the human daily exposure based on AUC exposure. Repeated oral administration of 4 and 6 mg/kg/day to monkeys for up to 20 weeks produced mortality and significant toxicity (marked weight loss, reduced red and white blood cell and platelet counts, multiple organ haemorrhage, gastrointestinal tract inflammation, lymphoid, and bone marrow atrophy). Repeated oral administration of 1 and 2 mg/kg/day to monkeys for up to 1 year produced reversible changes in bone marrow cellularity, a slight decrease in myeloid/erythroid cell ratio and thymic atrophy. Mild suppression of white blood cell count was observed at 1 mg/kg/day corresponding to approximately the same human dose based on AUC comparisons.

In vitro (bacterial mutation, human lymphocytes, mouse lymphoma, Syrian Hamster Embryo cell transformation) and in vivo (rat micronucleus) mutagenicity studies revealed no drug related effects at either the gene or chromosomal level. Carcinogenicity studies with lenalidomide have not been conducted.

Developmental toxicity studies were previously conducted in rabbits. In these studies, rabbits were administered 3, 10 and 20 mg/kg/day orally. An absence of the intermediate lobe of the lung was observed at 10 and 20 mg/kg/day with dose dependence and displaced kidneys were observed at 20 mg/kg/day. Although it was observed at maternotoxic levels they may be attributable to a direct effect. Soft tissue and skeletal variations in the foetuses were also observed at 10 and 20 mg/kg/day.

Therapeutic indications

Multiple myeloma

Lenalidomide as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.

Lenalidomide as combination therapy is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

Lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

Myelodysplastic syndromes

Lenalidomide as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

Mantle cell lymphoma

Lenalidomide as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Pharmacotherapeutic group

Other immunosuppressants. ATC code: L04AX04.

Pharmacodynamic properties

Pharmacotherapeutic group: Other immunosuppressants. ATC code: L04AX04.

Mechanism of action

The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes.

In MDS Del (5q), lenalidomide was shown to selectively inhibit the abnormal clone by increasing the apoptosis of Del (5q) cells.

Lenalidomide binds directly to cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex that includes deoxyribonucleic acid (DNA) damage-binding protein 1(DDB1), cullin 4 (CUL4), and regulator of cullins 1 (Roc1). In the presence of lenalidomide, cereblon binds substrate proteins Aiolos and Ikaros which are lymphoid transcriptional factors, leading to their ubiquitination and subsequent degradation resulting in cytotoxic and immunomodulatory effects.

Clinical efficacy and safety

Lenalidomide efficacy and safety have been evaluated in five phase III studies in newly diagnosed multiple myeloma, two phase III studies in relapsed refractory multiple myeloma, one phase III study and one phase II study in myelodysplastic syndromes and one phase II study in mantle cell lymphoma as described below.

Newly diagnosed multiple myeloma

- Lenalidomide maintenance in patients who have undergone ASCT

The efficacy and safety of lenalidomide maintenance was assessed in two phase 3 multicenter, randomised, double-blind 2-arm, parallel group, placebo-controlled studies: CALGB 100104 and IFM 2005-02

CALGB 100104

Patients between 18 and 70 years of age with active MM requiring treatment and without prior progression after initial therapy were eligible.

Patients were randomised 1:1 within 90-100 days after ASCT to receive either lenalidomide or placebo maintenance. The maintenance dose was 10 mg once daily on days 1-28 of repeated 28-day cycles (increased up to 15 mg once daily after 3 months in the absence of dose-limiting toxicity), and treatment was continued until disease progression.

The primary efficacy endpoint in the study was progression free survival (PFS) from randomisation to the date of progression or death, whichever occurred first; the study was not powered for the overall survival endpoint. In total 460 patients were randomised: 231 patients to Lenalidomide and 229 patients to placebo. The demographic and disease-related characteristics were balanced across both arms.

The study was unblinded upon the recommendations of the data monitoring committee after surpassing the threshold for a preplanned interim analysis of PFS. After unblinding, patients in the placebo arm were allowed to cross over to receive lenalidomide before disease progression.

The results of PFS at unblinding, following a preplanned interim analysis, using a cut-off of 17 December 2009 (15.5 months follow up) showed a 62% reduction in risk of disease progression or death favoring lenalidomide (HR = 0.38; 95% CI 0.27, 0.54; p <0.001). The median overall PFS was 33.9 months (95% CI NE, NE) in the lenalidomide arm versus 19.0 months (95% CI 16.2, 25.6) in the placebo arm.

The PFS benefit was observed both in the subgroup of patients with CR and in the subgroup of patients who had not achieved a CR.

The results for the study, using a cut-off of 1 February 2016, are presented in Table 6

Table 6: Summary of overall efficacy data

Lenalidomide

(N = 231)

Placebo

(N = 229)

Investigator-assessed PFS

Mediana PFS time, months (95% CI)b

56.9 (41.9, 71.7)

29,4 (20.7, 35.5)

HR [95% CI]c; p-valued

0.61 (0.48, 0.76); <0.001

PFS2e

Mediana PFS2 time, months (95% CI)b

80.2 (63.3, 101.8)

52.8 (41.3, 64.0)

HR [95% CI]c ; p-valued

0.61 (0.48, 0.78); <0.001

Overall survival

Mediana OS time, months (95% CI)b

111.0 (101.8, NE)

84.2 (71.0, 102.7)

8-year survival rate, % (SE)

60.9 (3.78)

44.6 (3.98)

HR [95% CI]c ; p-valued

0.61 (0.46, 0.81); <0.001

Follow-up

Medianf (min, max), months: all surviving patients

81.9 (0.0, 119.8)

81.0 (4.1, 119.5)

CI = confidence interval; HR = hazard ratio; max = maximum; min = minimum; NE = not estimable; OS = overall survival; PFS = progression-free survival;

a The median is based on the Kaplan-Meier estimate.

b The 95% CI about the median.

c Based on Cox proportional hazards model comparing the hazard functions associated with the indicated treatment arms.

d The p-value is based on the unstratified log-rank test of Kaplan-Meier curve differences between the indicated treatment arms.

e Exploratory endpoint (PFS2). Lenalidomide received by subjects in the placebo arm who crossed over prior to PD upon study unblinding was not considered as a second-line therapy.

f Median follow-up post-ASCT for all surviving subjects.

Data cuts: 17 Dec 2009 and 01 Feb 2016

IFM 2005-02

Patients aged < 65 years at diagnosis who had undergone ASCT and had achieved at least a stable disease response at the time of hematologic recovery were eligible. Patients were randomised 1:1 to receive either lenalidomide or placebo maintenance (10 mg once daily on days 1-28 of repeated 28-day cycles increased up to 15 mg once daily after 3 months in the absence of dose-limiting toxicity) following 2 courses of lenalidomide consolidation (25 mg/day, days 1-21 of a 28-day cycle). Treatment was to be continued until disease progression.

The primary endpoint was PFS defined from randomisation to the date of progression or death, whichever occurred first; the study was not powered for the overall survival endpoint. In total 614 patients were randomised: 307 patients to lenalidomide and 307 patients to placebo.

The study was unblinded upon the recommendations of the data monitoring committee after surpassing the threshold for a preplanned interim analysis of PFS. After unblinding, patients receiving placebo were not crossed over to lenalidomide therapy prior to progressive disease. The lenalidomide arm was discontinued, as a proactive safety measure, after observing an imbalance of SPMs.

The results of PFS at unblinding, following a preplanned interim analysis, using a cut-off of 7 July 2010 (31.4 months follow up) showed a 48% reduction in risk of disease progression or death favoring lenalidomide (HR = 0.52; 95% CI 0.41, 0.66; p <0.001). The median overall PFS was 40.1 months (95% CI 35.7, 42.4) in the lenalidomide arm versus 22.8 months (95% CI 20.7, 27.4) in the placebo arm.

The PFS benefit was less in the subgroup of patients with CR than in the subgroup of patients who had not achieved a CR.

The updated PFS, using a cut-off of 1 February 2016 (96.7 months follow up) continues to show a PFS advantage: HR = 0.57 (95% CI 0.47, 0.68; p < 0.001). The median overall PFS was 44.4 months (39.6, 52.0) in the lenalidomide arm versus 23.8 months (95% CI 21.2, 27.3) in the placebo arm. For PFS2, the observed HR was 0.80 (95% CI 0.66, 0.98; p = 0.026) for lenalidomide versus placebo. The median overall PFS2 was 69.9 months (95% CI 58.1, 80.0) in the lenalidomide arm versus 58.4 months (95% CI 51.1, 65.0) in the placebo arm. For OS, the observed HR was 0.90: (95% CI 0.72, 1.13; p = 0.355) for lenalidomide versus placebo. The median overall survival time was 105.9 months (95% CI 88.8, NE) in the lenalidomide arm versus 88.1 months (95% CI 80.7, 108.4) in the placebo arm.

- Lenalidomide in combination with dexamethasone in patients who are not eligible for stem cell transplantation

The safety and efficacy of lenalidomide was assessed in a phase III, multicenter, randomised, open-label, 3-arm study (MM-020) of patients who were at least 65 years of age or older or, if younger than 65 years of age, were not candidates for stem cell transplantation because they declined to undergo stem cell transplantation or stem cell transplantation is not available to the patient due to cost or other reason.The study (MM-020) compared lenalidomide and dexamethasone (Rd) given for 2 different durations of time (i.e., until progressive disease [Arm Rd] or for up to eighteen 28-day cycles [72 weeks, Arm Rd18]) to melphalan, prednisone and thalidomide (MPT) for a maximum of twelve 42-day cycles (72 weeks). Patients were randomised (1:1:1) to 1 of 3 treatment arms. Patients were stratified at randomisation by age (≤75 versus >75 years), stage (ISS Stages I and II versus Stage III), and country.

Patients in the Rd and Rd18 arms took lenalidomide 25 mg once daily on days 1 to 21 of 28-day cycles according to protocol arm. Dexamethasone 40 mg was dosed once daily on days 1, 8, 15, and 22 of each 28-day cycle. Initial dose and regimen for Rd and Rd18 were adjusted according to age and renal function. Patients >75 years received a dexamethasone dose of 20 mg once daily on days 1, 8, 15, and 22 of each 28-day cycle. All patients received prophylactic anticoagulation (low molecular weight heparin, warfarin, heparin, low-dose aspirin) during the study.

The primary efficacy endpoint in the study was progression free survival (PFS). In total 1623 patients were enrolled into the study, with 535 patients randomised to Rd, 541 patients randomised to Rd18 and 547 patients randomised to MPT. The demographics and disease-related baseline characteristics of the patients were well balanced in all 3 arms. In general, study subjects had advanced-stage disease: of the total study population, 41% had ISS stage III, 9% had severe renal insufficiency (creatinine clearance [CLcr] < 30 mL/min). The median age was 73 in the 3 arms.

In an updated analysis of PFS, PFS2 and OS using a cut off of 3 March 2014 where the median follow-up time for all surviving subjects was 45.5 months, the results of the study are presented in Table 7:

Table 7. Summary of overall efficacy data

Rd

(N = 535)

Rd18

(N = 541)

MPT

(N = 547)

Investigator-assessed PFS - (months)

Mediana PFS time, months (95% CI)b

26.0 (20.7, 29.7)

21.0 (19.7, 22.4)

21.9 (19.8, 23.9)

HR [95% CI]c; p-valued

Rd vs MPT

0.69 (0.59, 0.80); <0.001

Rd vs Rd18

0.71 (0.61, 0.83); <0.001

Rd18 vs MPT

0.99 (0.86, 1.14); 0.866

PFS2e - (months)

Mediana PFS2 time, months (95% CI)b

42.9 (38.1, 47.4)

40.0 (36.2, 44.2)

35.0 (30.4, 37.8)

HR [95% CI]c; p-valued

Rd vs MPT

0.74 (0.63, 0.86); <0.001

Rd vs Rd18

0.92 (0.78, 1.08); 0.316

Rd18 vs MPT

0.80 (0.69, 0.93); 0.004

Overall survival (months)

Mediana OS time, months (95% CI)b

58.9 (56.0, NE)

56.7 (50.1, NE)

48.5 (44.2, 52.0)

HR [95% CI]c; p-valued

Rd vs MPT

0.75 (0.62, 0.90); 0.002

Rd vs Rd18

0.91 (0.75, 1.09); 0.305

Rd18 vs MPT

0.83 (0.69, 0.99); 0.034

Follow-up (months)

Medianf (min, max): all patients

40.8 (0.0, 65.9)

40.1 (0.4, 65.7)

38.7 (0.0, 64.2)

Myeloma responseg n (%)

CR

81 (15.1)

77 (14.2)

51 (9.3)

VGPR

152 (28.4)

154 (28.5)

103 (18.8)

PR

169 (31.6)

166 (30.7)

187 (34.2)

Overall response: CR, VGPR, or PR

402 (75.1)

397 (73.4)

341 (62.3)

Duration of response - (months)h

Mediana (95% CI)b

35.0 (27.9, 43.4)

22.1 (20.3, 24.0)

22.3 (20.2, 24.9)

AMT = antimyeloma therapy; CI = confidence interval; CR = complete response; d = low-dose dexamethasone; HR = hazard ratio; IMWG = International Myeloma Working Group; IRAC = Independent Response Adjudication Committee; M = melphalan; max = maximum; min = minimum; NE = not estimable; OS = overall survival; P = prednisone; PFS = progression-free survival; PR = partial response; R = lenalidomide; Rd = Rd given until documentation of progressive disease; Rd18 = Rd given for 18 cycles; SE = standard error; T = thalidomide; VGPR = very good partial response; vs = versus.

a The median is based on the Kaplan-Meier estimate.

b The 95% CI about the median.

c Based on Cox proportional hazards model comparing the hazard functions associated with the indicated treatment arms.

d The p-value is based on the unstratified log-rank test of Kaplan-Meier curve differences between the indicated treatment arms.

e Exploratory endpoint (PFS2)

f The median is the univariate statistic without adjusting for censoring.

g Best assessment of adjudicated response during the treatment phase of the study (for definitions of each response category, Data cut-off date = 24 May 2013).

h data cut 24 May 2013

- Lenalidomide in combination with melphalan and prednisone followed by maintenance therapy in patients who are not eligible for transplant

The safety and efficacy of lenalidomide was assessed in a phase III multicenter, randomised double blind 3 arm study (MM-015) of patients who were 65 years or older and had a serum creatinine < 2.5 mg/dL. The study compared lenalidomide in combination with melphalan and prednisone (MPR) with or without lenalidomide maintenance therapy until disease progression, to that of melphalan and prednisone for a maximum of 9 cycles. Patients were randomised in a 1:1:1 ratio to one of 3 treatment arms. Patients were stratified at randomisation by age (≤ 75 vs. > 75 years) and stage (ISS; Stages I and II vs. stage III).

This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1 to 4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1 to 4 of repeated 28-day cycles; and lenalidomide 10 mg/day orally on days 1 to 21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenance therapy starting with lenalidomide 10 mg orally on days 1 to 21 of repeated 28-day cycles until disease progression.

The primary efficacy endpoint in the study was progression free survival (PFS). In total 459 patients were enrolled into the study, with 152 patients randomised to MPR+R, 153 patients randomised to MPR+p and 154 patients randomised to MPp+p. The demographics and disease-related baseline characteristics of the patients were well balanced in all 3 arms; notably, approximately 50% of the patients enrolled in each arm had the following characteristics; ISS Stage III, and creatinine clearance < 60 mL/min. The median age was 71 in the MPR+R and MPR+p arms and 72 in the MPp+p arm.

In an analysis of PFS, PFS2, OS using a cut-off of April 2013 where the median follow up time for all surviving subjects was 62.4 months, the results of the study are presented in Table 8:

Table 8. Summary of overall efficacy data

MPR+R

(N = 152)

MPR+p

(N = 153)

MPp +p

(N = 154)

Investigator-assessed PFS - (months)

Mediana PFS time, months (95% CI)

27.4 (21.3, 35.0)

14.3 (13.2, 15.7)

13.1 (12.0, 14.8)

HR [95% CI]; p-value

MPR+R vs MPp+p

0.37 (0.27, 0.50); <0.001

MPR+R vs MPR+p

0.47 (0.35, 0.65); <0.001

MPR+p vs MPp +p

0.78 (0.60, 1.01); 0.059

PFS2 - (months) ¤

Mediana PFS2 time, months (95% CI)

39.7 (29.2, 48.4)

27.8 (23.1, 33.1)

28.8 (24.3, 33.8)

HR [95% CI]; p-value

MPR+R vs MPp+p

0.70 (0.54, 0.92); 0.009

MPR+R vs MPR+p

0.77 (0.59, 1.02); 0.065

MPR+p vs MPp +p

0.92 (0.71, 1.19); 0.051

Overall survival (months)

Mediana OS time, months (95% CI)

55.9 (49.1, 67.5)

51.9 (43.1, 60.6)

53.9 (47.3, 64.2)

HR [95% CI]; p-value

MPR+R vs MPp+p

0.95 (0.70, 1.29); 0.736

MPR+R vs MPR+p

0.88 (0.65, 1.20); 0.43

MPR+p vs MPp +p

1.07 (0.79, 1.45); 0.67

Follow-up (months)

Median (min, max): all patients

48.4 (0.8, 73.8)

46.3 (0.5, 71.9)

50.4 (0.5, 73.3)

Investigator-assessed Myeloma response n

(%)

CR

30 (19.7)

17 (11.1)

9 (5.8)

PR

90 (59.2)

99 ( 64.7)

75 (48.7)

Stable Disease (SD)

24 (15.8)

31 (20.3)

63 (40.9)

Response Not Evaluable (NE)

8 (5.3)

4 (2.6)

7 (4.5)

Investigator-assessed Duration of response

(CR+PR) - (months)

Mediana (95% CI)

26.5 (19.4, 35.8)

12.4 (11.2, 13.9)

12.0 (9.4, 14.5)

CI = confidence interval; CR = complete response; HR = Hazard Rate; M = melphalan; NE = not estimable; OS = overall survival; p = placebo; P = prednisone; PD = progressive disease; PR = partial response; R = lenalidomide; SD = stable disease; VGPR = very good partial response.

a The median is based on the Kaplan-Meier estimate

¤PFS2 (an exploratory endpoint) was defined for all patients (ITT) as time from randomisation to start of 3rd line antimyeloma therapy (AMT) or death for all randomised patients

Supportive newly diagnosed multiple myeloma studies

An open-label, randomised, multicenter, phase III study (ECOG E4A03) was conducted in 445 patients with newly diagnosed multiple myeloma; 222 patients were randomised to the lenalidomide/low dose dexamethasone arm, and 223 were randomised to the lenalidomide/standard dose dexamethasone arm. Patients randomised to the lenalidomide/standard dose dexamethasone arm received lenalidomide 25 mg/day, days 1 to 21 every 28 days plus dexamethasone 40 mg/day on days 1 to 4, 9 to 12, and 17 to 20 every 28 days for the first four cycles. Patients randomised to the lenalidomide/low dose dexamethasone arm received lenalidomide 25 mg/day, days 1 to 21 every 28 days plus low dose dexamethasone - 40 mg/day on days 1, 8, 15, and 22 every 28 days. In the lenalidomide/low dose dexamethasone group, 20 patients (9.1%) underwent at least one dose interruption compared to 65 patients (29.3%) in the lenalidomide/standard dose dexamethasone arm.

In a post-hoc analysis, lower mortality was observed in the lenalidomide/low dose dexamethasone arm 6.8% (15/220) compared to the lenalidomide/standard dose dexamethasone arm 19.3% (43/223), in the newly diagnosed multiple myeloma patient population, with a median follow up of 72.3 weeks.

However with a longer follow-up, the difference in overall survival in favour of lenalidomide/ low dose dexamethasone tends to decrease.

Multiple myeloma with at least one prior therapy

The efficacy and safety of lenalidomide were evaluated in two phase III multi-centre, randomised, double- blind, placebo-controlled, parallel-group controlled studies (MM-009 and MM-010) of lenalidomide plus dexamethasone therapy versus dexamethasone alone in previously treated patients with multiple myeloma. Out of 353 patients in the MM-009 and MM-010 studies who received lenalidomide/dexamethasone, 45.6% were aged 65 or over. Of the 704 patients evaluated in the MM-009 and MM-010 studies, 44.6% were aged 65 or over.

In both studies, patients in the lenalidomide/dexamethasone (len/dex) group took 25 mg of lenalidomide orally once daily on days 1 to 21 and a matching placebo capsule once daily on days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone (placebo/dex) group took 1 placebo capsule on days 1 to 28 of each 28-day cycle. Patients in both treatment groups took 40 mg of dexamethasone orally once daily on days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. The dose of dexamethasone was reduced to 40 mg orally once daily on days 1 to 4 of each 28-day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression. In both studies, dose adjustments were allowed based on clinical and laboratory finding.

The primary efficacy endpoint in both studies was time to progression (TTP). In total, 353 patients were evaluated in the MM-009 study; 177 in the len/dex group and 176 in the placebo/dex group and, in total, 351 patients were evaluated in the MM-010 study; 176 in the len/dex group and 175 in the placebo/dex group.

In both studies, the baseline demographic and disease-related characteristics were comparable between the len/dex and placebo/dex groups. Both patient populations presented a median age of 63 years, with a comparable male to female ratio. The ECOG performance status was comparable between both groups, as was the number and type of prior therapies.

Pre-planned interim analyses of both studies showed that len/dex was statistically significantly superior (p < 0.00001) to dexamethasone alone for the primary efficacy endpoint, TTP (median follow-up duration of 98.0 weeks). Complete response and overall response rates in the len/dex arm were also significantly higher than the placebo/dex arm in both studies. Results of these analyses subsequently led to an unblinding in both studies, in order to allow patients in the placebo/dex group to receive treatment with the len/dex combination.

An extended follow-up efficacy analysis was conducted with a median follow-up of 130.7 weeks. Table 9 summarises the results of the follow-up efficacy analyses - pooled studies MM-009 and MM-010.

In this pooled extended follow-up analysis, the median TTP was 60.1 weeks (95% CI: 44.3, 73.1) in patients treated with len/dex (N = 353) versus 20.1 weeks (95% CI: 17.7, 20.3) in patients treated with placebo/dex (N = 351). The median progression free survival was 48.1 weeks (95% CI: 36.4, 62.1) in patients treated with len/dex versus 20.0 weeks (95% CI: 16.1, 20.1) in patients treated with placebo/dex. The median duration of treatment was 44.0 weeks (min: 0.1, max: 254.9) for len/dex and 23.1 weeks (min: 0.3, max: 238.1) for placebo/dex. Complete response (CR), partial response (PR) and overall response (CR+PR) rates

in the len/dex arm remain significantly higher than in the placebo/dex arm in both studies. The median overall survival in the extended follow-up analysis of the pooled studies is 164.3 weeks (95% CI: 145.1, 192.6) in patients treated with len/dex versus 136.4 weeks (95% CI: 113.1, 161.7) in patients treated with placebo/dex. Despite the fact that 170 out of the 351 patients randomised

Pharmacokinetic properties

Lenalidomide has an asymmetric carbon atom and can therefore exist as the optically active forms S(-) and R(+). Lenalidomide is produced as a racemic mixture. Lenalidomide is generally more soluble in organic solvents but exhibits the greatest solubility in 0.1N HCl buffer.

Absorption

Lenalidomide is rapidly absorbed following oral administration in healthy volunteers, under fasting conditions, with maximum plasma concentrations occurring between 0.5 and 2 hours post-dose. In patients, as well as in healthy volunteers, the maximum concentration (Cmax) and area-under-the-concentration time curve (AUC) increase proportionally with increases in dose. Multiple dosing does not cause marked medicinal product accumulation. In plasma, the relative exposures of the S- and R- enantiomers of lenalidomide are approximately 56% and 44%, respectively.

Co-administration with a high-fat and high-calorie meal in healthy volunteers reduces the extent of absorption, resulting in an approximately 20% decrease in area under the concentration versus time curve (AUC) and 50% decrease in Cmax in plasma. However, in the main multiple myeloma and myelodysplastic syndromes registration trials where the efficacy and safety were established for lenalidomide, the medicinal product was administered without regard to food intake. Thus, lenalidomide can be administered with or without food.

Population pharmacokinetic analyses indicate that the oral absorption rate of lenalidomide is similar among MM, MDS and MCL patients.

Distribution

In vitro (14C)-lenalidomide binding to plasma proteins was low with mean plasma protein binding at 23% and 29% in multiple myeloma patients and healthy volunteers, respectively.

Lenalidomide is present in human semen (< 0.01% of the dose) after administration of 25 mg/day and the medicinal product is undetectable in semen of a healthy subject 3 days after stopping the substance.

Biotransformation and elimination

Results from human in vitro metabolism studies indicate that lenalidomide is not metabolised by cytochrome P450 enzymes suggesting that administration of lenalidomide with medicinal products that inhibit cytochrome P450 enzymes is not likely to result in metabolic medicinal product interactions in humans. In vitro studies indicate that lenalidomide has no inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A, or UGT1A1. Therefore, lenalidomide is unlikely to cause any clinically relevant medicinal product interactions when co-administered with substrates of these enzymes.

In vitro studies indicate that lenalidomide is not a substrate of human breast cancer resistance protein (BCRP), multidrug resistance protein (MRP) transporters MRP1, MRP2, or MRP3, organic anion transporters (OAT) OAT1 and OAT3, organic anion transporting polypeptide 1B1 (OATP1B1), organic cation transporters (OCT) OCT1 and OCT2, multidrug and toxin extrusion protein (MATE) MATE1, and organic cation transporters novel (OCTN) OCTN1 and OCTN2.

In vitro studies indicate that lenalidomide has no inhibitory effect on human bile salt export pump (BSEP), BCRP, MRP2, OAT1, OAT3, OATP1B1, OATP1B3, and OCT2.

A majority of lenalidomide is eliminated through urinary excretion. The contribution of renal excretion to total clearance in subjects with normal renal function was 90%, with 4% of lenalidomide eliminated in faeces.

Lenalidomide is poorly metabolized as 82% of the dose is excreted unchanged in urine. Hydroxy- lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively. The renal clearance of lenalidomide exceeds the glomerular filtration rate and therefore is at least actively secreted to some extent.

At doses of 5 to 25 mg/day, half-life in plasma is approximately 3 hours in healthy volunteers and ranges from 3 to 5 hours in patients with multiple myeloma, myelodysplastic syndromes or mantle cell lymphoma.

Older people

No dedicated clinical studies have been conducted to evaluate pharmacokinetics of lenalidomide in the elderly. Population pharmacokinetic analyses included patients with ages ranging from 39 to 85 years old and indicate that age does not influence lenalidomide clearance (exposure in plasma). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it would be prudent to monitor renal function.

Renal impairment

The pharmacokinetics of lenalidomide was studied in subjects with renal impairment due to nonmalignant conditions.

Hepatic impairment

Population pharmacokinetic analyses included patients with mild hepatic impairment (N=16, total bilirubin >1 to ≤1.5 x ULN or AST > ULN) and indicate that mild hepatic impairment does not influence lenalidomide clearance (exposure in plasma). There are no data available for patients with moderate to severe hepatic impairment.

Other intrinsic factors

Population pharmacokinetic analyses indicate that body weight (33- 135 kg), gender, race and type of haematological malignancy (MM, MDS or MCL) do not have a clinically relevant effect on lenalidomide clearance in adult patients.

Name of the medicinal product

Lenalidomide

Qualitative and quantitative composition

Lenalidomide

Special warnings and precautions for use

Pregnancy warning

Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. Lenalidomide induced in monkeys malformations similar to those described with thalidomide. If lenalidomide is taken during pregnancy, a teratogenic effect of lenalidomide in humans is expected.

The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.

Criteria for women of non-childbearing potential

A female patient or a female partner of a male patient is considered to have childbearing potential unless she meets at least one of the following criteria:

- Age > 50 years and naturally amenorrhoeic for > 1 year (Amenorrhoea following cancer therapy or during breast-feeding does not rule out childbearing potential).

- Premature ovarian failure confirmed by a specialist gynaecologist

- Previous bilateral salpingo-oophorectomy, or hysterectomy

- XY genotype, Turner syndrome, uterine agenesis.

Counselling

For women of childbearing potential, lenalidomide is contraindicated unless all of the following are met:

- She understands the expected teratogenic risk to the unborn child

- She understands the need for effective contraception, without interruption, 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment

- Even if a woman of childbearing potential has amenorrhea she must follow all the advice on effective contraception

- She should be capable of complying with effective contraceptive measures

- She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy

- She understands the need to commence the treatment as soon as lenalidomide is dispensed following a negative pregnancy test

- She understands the need and accepts to undergo pregnancy testing every 4 weeks except in case of confirmed tubal sterilisation

- She acknowledges that she understands the hazards and necessary precautions associated with the use of lenalidomide.

For male patients taking lenalidomide, pharmacokinetic data has demonstrated that lenalidomide is present in human semen at extremely low levels during treatment and is undetectable in human semen 3 days after stopping the substance in the healthy subject. As a precaution and taking into account special populations with prolonged elimination time such as renal impairment, all male patients taking lenalidomide must meet the following conditions:

- Understand the expected teratogenic risk if engaged in sexual activity with a pregnant woman or a woman of childbearing potential

- Understand the need for the use of a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential not using effective contraception (even if the man has had a vasectomy), during treatment and for 1 week after dose interruptions and/or cessation of treatment.

- Understand that if his female partner becomes pregnant whilst he is taking Lenalidomide or shortly after he has stopped taking Lenalidomide, he should inform his treating physician immediately and that it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice.

The prescriber must ensure that for women of childbearing potential:

- The patient complies with the conditions of the Pregnancy Prevention Programme, including confirmation that she has an adequate level of understanding

- The patient has acknowledged the aforementioned conditions.

Contraception

Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and until 4 weeks after lenalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis. If not established on effective contraception, the patient must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.

The following can be considered to be examples of suitable methods of contraception:

- Implant

- Levonorgestrel-releasing intrauterine system (IUS)

- Medroxyprogesterone acetate depot

- Tubal sterilisation

- Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses

- Ovulation inhibitory progesterone-only pills (i.e. desogestrel)

). If a patient is currently using combined oral contraception the patient should switch to one of the effective methods listed above. The risk of venous thromboembolism continues for 4−6 weeks after discontinuing combined oral contraception. The efficacy of contraceptive steroids may be reduced during co-treatment with dexamethasone.

Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia.

Copper-releasing intrauterine devices are generally not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with neutropenia or thrombocytopenia.

Pregnancy testing

According to local practice, medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL must be performed for women of childbearing potential as outlined below. This requirement includes women of childbearing potential who practice absolute and continuous abstinence. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of lenalidomide to women of childbearing potential should occur within 7 days of the prescription.

Prior to starting treatment

A medically supervised pregnancy test should be performed during the consultation, when lenalidomide is prescribed, or in the 3 days prior to the visit to the prescriber once the patient had been using effective contraception for at least 4 weeks. The test should ensure the patient is not pregnant when she starts treatment with lenalidomide.

Follow-up and end of treatment

A medically supervised pregnancy test should be repeated every 4 weeks, including 4 weeks after the end of treatment, except in the case of confirmed tubal sterilisation. These pregnancy tests should be performed on the day of the prescribing visit or in the 3 days prior to the visit to the prescriber.

Additional precautions

Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment for safe disposal.

Patients should not donate blood during therapy or for 1 week following discontinuation of lenalidomide.

Educational materials, prescribing and dispensing restrictions

In order to assist patients in avoiding foetal exposure to lenalidomide, the marketing authorisation holder will provide educational material to health care professionals to reinforce the warnings about the expected teratogenicity of lenalidomide, to provide advice on contraception before therapy is started, and to provide guidance on the need for pregnancy testing. The prescriber must inform male and female patients about the expected teratogenic risk and the strict pregnancy prevention measures as specified in the Pregnancy Prevention Programme and provide patients with appropriate patient educational brochure, patient card and/or equivalent tool in accordance to the national implemented patient card system. A national controlled distribution system has been implemented in collaboration with each National Competent Authority. The controlled distribution system includes the use of a patient card and/or equivalent tool for prescribing and/or dispensing controls, and the collecting of detailed data relating to the indication in order to monitor closely the off-label use within the national territory. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of lenalidomide to women of childbearing potential should occur within 7 days of the prescription and following a medically supervised negative pregnancy test result.

Other special warnings and precautions for use

Myocardial infarction

Myocardial infarction has been reported in patients receiving lenalidomide, particularly in those with known risk factors and within the first 12 months when used in combination with dexamethasone. Patients with known risk factors - including prior thrombosis - should be closely monitored, and action should be taken to try to minimize all modifiable risk factors (eg. smoking, hypertension, and hyperlipidaemia).

Venous and arterial thromboembolic events

In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) and was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone.

In patients with multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma, treatment with lenalidomide monotherapy was associated with a lower risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) than in patients with multiple myeloma treated with lenalidomide in combination therapy.

In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event) and was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone. The risk of ATE is lower in patients with multiple myeloma treated with lenalidomide monotherapy than in patients with multiple myeloma treated with lenalidomide in combination therapy.

Consequently, patients with known risk factors for thromboembolism - including prior thrombosis - should be closely monitored. Action should be taken to try to minimize all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia). Concomitant administration of erythropoietic agents or previous history of thromboembolic events may also increase thrombotic risk in these patients. Therefore, erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone. A haemoglobin concentration above 12 g/dl should lead to discontinuation of erythropoietic agents.

Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, arm or leg swelling. Prophylactic antithrombotic medicines should be recommended, especially in patients with additional thrombotic risk factors. The decision to take antithrombotic prophylactic measures should be made after careful assessment of an individual patient's underlying risk factors.

If the patient experiences any thromboembolic events, treatment must be discontinued and standard anticoagulation therapy started. Once the patient has been stabilised on the anticoagulation treatment and any complications of the thromboembolic event have been managed, the lenalidomide treatment may be restarted at the original dose dependent upon a benefit risk assessment. The patient should continue anticoagulation therapy during the course of lenalidomide treatment.

Neutropenia and thrombocytopenia

The major dose limiting toxicities of lenalidomide include neutropenia and thrombocytopenia. A complete blood cell count, including white blood cell count with differential count, platelet count, haemoglobin, and haematocrit should be performed at baseline, every week for the first 8 weeks of lenalidomide treatment and monthly thereafter to monitor for cytopenias. In mantle cell lymphoma patients, the monitoring scheme should be every 2 weeks in Cycles 3 and 4, and then at the start of each cycle. A dose reduction may be required.

In case of neutropenia, the physician should consider the use of growth factors in patient management. Patients should be advised to promptly report febrile episodes.

).

Co-administration of lenalidomide with other myelosuppressive agents should be undertaken with caution.

- Newly diagnosed multiple myeloma: patients who have undergone ASCT treated with lenalidomide maintenance

The adverse reactions from CALGB 100104 included events reported post-high dose melphalan and ASCT (HDM/ASCT) as well as events from the maintenance treatment period. A second analysis identified events that occurred after the start of maintenance treatment. In IFM 2005-02, the adverse reactions were from the maintenance treatment period only.

Overall, grade 4 neutropenia was observed at a higher frequency in the lenalidomide maintenance arms compared to the placebo maintenance arms in the 2 studies evaluating lenalidomide maintenance in NDMM patients who have undergone ASCT (32.1% vs 26.7% [16.1% vs 1.8% after the start of maintenance treatment] in CALGB 100104 and 16.4% vs 0.7% in IFM 2005-02, respectively). Treatment-emergent AEs of neutropenia leading to lenalidomide discontinuation were reported in 2.2% of patients in CALGB 100104 and 2.4% of patients in IFM 2005-02, respectively. Grade 4 febrile neutropenia was reported at similar frequencies in the lenalidomide maintenance arms compared to placebo maintenance arms in both studies (0.4% vs 0.5% [0.4% vs 0.5% after the start of maintenance treatment] in CALGB 100104 and 0.3% vs 0% in IFM 2005-02, respectively). Patients should be advised to promptly report febrile episodes, a treatment interruption and/or dose reductions may be required.

Grade 3 or 4 thrombocytopenia was observed at a higher frequency in the lenalidomide maintenance arms compared to the placebo maintenance arms in studies evaluating lenalidomide maintenance in NDMM patients who have undergone ASCT (37.5% vs 30.3% [17.9% vs 4.1% after the start of maintenance treatment] in CALGB 100104 and 13.0% vs 2.9% in IFM 2005-02, respectively).).

- Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with low dose dexamethasone

Grade 4 neutropenia was observed in the lenalidomide arms in combination with low dose dexamethasone to a lesser extent than in the comparator arm (8.5% in the Rd [continuous treatment] and Rd18 [treatment for 18 four-week cycles] compared with 15% in the melphalan/prednisone/thalidomide arm, see section 4.8).).

Grade 3 or 4 thrombocytopenia was observed to a lesser extent in the Rd and Rd18 arms than in the comparator arm (8.1% vs 11.1%, respectively).

- Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with lenalidomide in combination with melphalan and prednisone

The combination of lenalidomide with melphalan and prednisone in clinical trials of newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (34.1% in melphalan, prednisone and lenalidomide arm followed by lenalidomide [MPR+R] and melphalan, prednisone and lenalidomide followed by placebo [MPR+p] treated patients compared with 7.8% in MPp+p-treated patients; see section 4.8).).

The combination of lenalidomide with melphalan and prednisone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (40.4% in MPR+R/MPR+p treated patients, compared with 13.7% in MPp+p-treated patients; see section 4.8).

- Multiple myeloma: patients with at least one prior therapy

The combination of lenalidomide with dexamethasone in multiple myeloma patients with at least one prior therapy is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone- treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8).).

The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients; see section 4.8).

- Myelodysplastic syndromes

Lenalidomide treatment in myelodysplastic syndromes patients is associated with a higher incidence of grade 3 and 4 neutropenia and thrombocytopenia compared to patients on placebo.

- Mantle cell lymphoma

Lenalidomide treatment in mantle cell lymphoma patients is associated with a higher incidence of grade 3 and 4 neutropenia compared with patients on the control arm.

Thyroid disorders

Cases of hypothyroidism and cases of hyperthyroidism have been reported. Optimal control of co-morbid conditions influencing thyroid function is recommended before start of treatment. Baseline and ongoing monitoring of thyroid function is recommended.

Peripheral neuropathy

Lenalidomide is structurally related to thalidomide, which is known to induce severe peripheral neuropathy. There was no increase in peripheral neuropathy observed with long term use of lenalidomide for the treatment of newly diagnosed multiple myeloma.

Tumour flare reaction and tumour lysis syndrome

Because lenalidomide has anti-neoplastic activity the complications of tumour lysis syndrome (TLS) may occur. TLS and tumour flare reaction (TFR) have commonly been observed in patients with chronic lymphocytic leukemia (CLL), and uncommonly in patients with lymphomas, who were treated with lenalidomide. Fatal instances of TLS have been reported during treatment with lenalidomide. The patients at risk of TLS and TFR are those with high tumour burden prior to treatment. Caution should be practiced when introducing these patients to lenalidomide. These patients should be monitored closely, especially during the first cycle or dose-escalation, and appropriate precautions taken. There have been rare reports of TLS in patients with MM treated with lenalidomide, and no reports in patients with MDS treated with lenalidomide.

Tumour burden

- Mantle cell lymphoma

Lenalidomide is not recommended for the treatment of patients with high tumour burden if alternative treatment options are available.

Early death

In study MCL-002 there was overall an apparent increase in early (within 20 weeks) deaths. Patients with high tumour burden at baseline are at increased risk of early death, there were 16/81 (20%) early deaths in the lenalidomide arm and 2/28 (7%) early deaths in the control arm. Within 52 weeks corresponding figures were 32/81 (40%) and 6/28 (21%).

Adverse events

In study MCL-002, during treatment cycle 1, 11/81 (14%) patients with high tumour burden were withdrawn from therapy in the lenalidomide arm vs. 1/28 (4%) in the control group. The main reason for treatment withdrawal for patients with high tumour burden during treatment cycle 1 in the lenalidomide arm was adverse events, 7/11 (64%).

Patients with high tumour burden should therefore be closely monitored for adverse reactions including signs of tumour flare reaction (TFR). High tumour burden was defined as at least one lesion >5 cm in diameter or 3 lesions >3 cm.

Tumour flare reaction

- Mantle cell lymphoma

Careful monitoring and evaluation for TFR is recommended. Patients with high mantle cell lymphoma International Prognostic Index (MIPI) at diagnosis or bulky disease (at least one lesion that is > 7 cm in the longest diameter) at baseline may be at risk of TFR. Tumour flare reaction may mimic progression of disease (PD). Patients in studies MCL-002 and MCL-001 that experienced Grade 1 and 2 TFR were treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. The decision to take therapeutic measures for TFR should be made after careful clinical assessment of the individual patient.

Allergic reactions

Cases of allergic reaction/hypersensitivity reactions have been reported in patients treated with lenalidomide. Patients who had previous allergic reactions while treated with thalidomide should be monitored closely, as a possible cross-reaction between lenalidomide and thalidomide has been reported in the literature.

Severe skin reactions

Severe cutaneous reactions including SJS, and TEN and DRESS have been reported with the use of lenalidomide. Patients should be advised of the signs and symptoms of these reactions by their prescribers and should be told to seek medical attention immediately if they develop these symptoms. Lenalidomide must be discontinued for exfoliative or bullous rash, or if SJS, TEN or DRESS is suspected, and should not be resumed following discontinuation for these reactions. Interruption or discontinuation of lenalidomide should be considered for other forms of skin reaction depending on severity. Patients with a history of severe rash associated with thalidomide treatment should not receive lenalidomide.

Lactose intolerance

Lenalidomide capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

Second primary malignancies

An increase of second primary malignancies (SPM) has been observed in clinical trials in previously treated myeloma patients receiving lenalidomide/dexamethasone (3.98 per 100 person-years) compared to controls (1.38 per 100 person-years). Non-invasive SPM comprise basal cell or squamous cell skin cancers. Most of the invasive SPMs were solid tumour malignancies.

In clinical trials of newly diagnosed multiple myeloma patients not eligible for transplant, a 4.9-fold increase in incidence rate of hematologic SPM (cases of AML, MDS) has been observed in patients receiving lenalidomide in combination with melphalan and prednisone until progression (1.75 per 100 person-years) compared with melphalan in combination with prednisone (0.36 per 100 person-years).

A 2.12-fold increase in incidence rate of solid tumour SPM has been observed in patients receiving lenalidomide (9 cycles) in combination with melphalan and prednisone (1.57 per 100 person-years) compared with melphalan in combination with prednisone (0.74 per 100 person-years).

In patients receiving lenalidomide in combination with dexamethasone until progression or for 18 months, the hematologic SPM incidence rate (0.16 per 100 person-years) was not increased as compared to thalidomide in combination with melphalan and prednisone (0.79 per 100 person-years).

A 1.3-fold increase in incidence rate of solid tumour SPM has been observed in patients receiving lenalidomide in combination with dexamethasone until progression or for 18 months (1.58 per 100 person- years) compared to thalidomide in combination with melphalan and prednisone (1.19 per 100 person-years).

The increased risk of secondary primary malignancies associated with lenalidomide is relevant also in the context of NDMM after stem cell transplantation. Though this risk is not yet fully characterized, it should be kept in mind when considering and using Lenalidomide in this setting.

The incidence rate of hematologic malignancies, most notably AML, MDS and B-cell malignancies (including Hodgkin's lymphoma), was 1.31 per 100 person-years for the lenalidomide arms and 0.58 per 100 person-years for the placebo arms (1.02 per 100 person-years for patients exposed to lenalidomide after ASCT and 0.60 per 100 person-years for patients not-exposed to lenalidomide after ASCT). The incidence rate of solid tumour SPMs was 1.36 per 100 person-years for the lenalidomide arms and 1.05 per 100 person- years for the placebo arms (1.26 per 100 person-years for patients exposed to lenalidomide after ASCT and 0.60 per 100 person-years for patients not-exposed to lenalidomide after ASCT).

The risk of occurrence of hematologic SPM must be taken into account before initiating treatment with lenalidomide either in combination with melphalan or immediately following high-dose melphalan and ASCT. Physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of SPM and institute treatment as indicated.

Progression to acute myeloid leukaemia in low- and intermediate-1-risk MDS

- Karyotype

Baseline variables including complex cytogenetics are associated with progression to AML in subjects who are transfusion dependent and have a Del (5q) abnormality. In a combined analysis of two clinical trials of lenalidomide in low- or intermediate-1-risk myelodysplastic syndromes, subjects who had a complex cytogenetics had the highest estimated 2-year cumulative risk of progression to AML (38.6%). The estimated 2-year rate of progression to AML in patients with an isolated Del (5q) abnormality was 13.8%, compared to 17.3% for patients with Del (5q) and one additional cytogenetic abnormality.

As a consequence, the benefit/risk ratio of lenalidomide when MDS is associated with Del (5q) and complex cytogenetics is unknown.

- TP53 status

A TP53 mutation is present in 20 to 25% of lower-risk MDS Del 5q patients and is associated with a higher risk of progression to acute myeloid leukaemia (AML). In a post-hoc analysis of a clinical trial of lenalidomide in low- or intermediate-1-risk myelodysplastic syndromes (MDS-004), the estimated 2-year rate of progression to AML was 27.5 % in patients with IHC-p53 positivity (1% cut-off level of strong nuclear staining, using immunohistochemical assessment of p53 protein as a surrogate for TP53 mutation status) and 3.6% in patients with IHC-p53 negativity (p=0.0038)

Progression to other malignancies in mantle cell lymphoma

In mantle cell lymphoma, AML, B-cell malignancies and non-melanoma skin cancer (NMSC) are potential risks.

Hepatic disorders

Hepatic failure, including fatal cases, has been reported in patients treated with lenalidomide in combination therapy: acute hepatic failure, toxic hepatitis, cytolytic hepatitis, cholestatic hepatitis, and mixed cytolytic/cholestatic hepatitis have been reported. The mechanisms of severe drug-induced hepatotoxicity remain unknown although, in some cases, pre-existing viral liver disease, elevated baseline liver enzymes, and possibly treatment with antibiotics might be risk factors.

Abnormal liver function tests were commonly reported and were generally asymptomatic and reversible upon dosing interruption. Once parameters have returned to baseline, treatment at a lower dose may be considered.

Lenalidomide is excreted by the kidneys. It is important to dose adjust patients with renal impairment in order to avoid plasma levels which may increase the risk for higher haematological adverse reactions or hepatotoxicity. Monitoring of liver function is recommended, particularly when there is a history of or concurrent viral liver infection or when lenalidomide is combined with medicinal products known to be associated with liver dysfunction.

Infection with or without neutropenia

Patients with multiple myeloma are prone to develop infections including pneumonia. A higher rate of infections was observed with lenalidomide in combination with dexamethasone than with MPT in patients with NDMM who are not eligible for transplant, and with lenalidomide maintenance compared to placebo in patients with NDMM who had undergone ASCT. Grade > 3 infections occurred within the context of neutropenia in less than one-third of the patients. Patients with known risk factors for infections should be closely monitored. All patients should be advised to seek medical attention promptly at the first sign of infection (eg, cough, fever, etc) thereby allowing for early management to reduce severity.

Cases of viral reactivation have been reported in patients receiving lenalidomide, including serious cases of herpes zoster or hepatitis B virus (HBV) reactivation.

Some of the cases of viral reactivation had a fatal outcome.

Some of the cases of herpes zoster reactivation resulted in disseminated herpes zoster, meningitis herpes zoster or ophthalmic herpes zoster requiring a temporary hold or permanent discontinuation of the treatment with lenalidomide and adequate antiviral treatment.

Reactivation of hepatitis B has been reported rarely in patients receiving lenalidomide who have previously been infected with the hepatitis B virus (HBV). Some of these cases have progressed to acute hepatic failure resulting in discontinuation of lenalidomide and adequate antiviral treatment. Hepatitis B virus status should be established before initiating treatment with lenalidomide. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended. Caution should be exercised when lenalidomide is used in patients previously infected with HBV, including patients who are anti-HBc positive but HBsAg negative. These patients should be closely monitored for signs and symptoms of active HBV infection throughout therapy.

- Newly diagnosed multiple myeloma patients

There was a higher rate of intolerance (grade 3 or 4 adverse events, serious adverse events, discontinuation) in patients with age > 75 years, ISS stage III, ECOG PS≤2 or CLcr<60 mL/min when lenalidomide is given in combination. Patients should be carefully assessed for their ability to tolerate lenalidomide in combination, with consideration to age, ISS stage III, ECOG PS≤2 or CLcr<60 mL/min.

Cataract

Cataract has been reported with a higher frequency in patients receiving lenalidomide in combination with dexamethasone particularly when used for a prolonged time. Regular monitoring of visual ability is recommended.

Effects on ability to drive and use machines

Lenalidomide has minor or moderate influence on the ability to drive and use machines. Fatigue, dizziness, somnolence, vertigo and blurred vision have been reported with the use of lenalidomide. Therefore, caution is recommended when driving or operating machines.

Dosage (Posology) and method of administration

Lenalidomide treatment should be supervised by a physician experienced in the use of anti-cancer therapies.

For all indications described below:

- Dose is modified based upon clinical and laboratory findings.

- Dose adjustments, during treatment and restart of treatment, are recommended to manage grade 3 or 4 thrombocytopenia, neutropenia, or other grade 3 or 4 toxicity judged to be related to lenalidomide.

- In case of neutropenia, the use of growth factors in patient management should be considered.

- If less than 12 hours has elapsed since missing a dose, the patient can take the dose. If more than 12 hours has elapsed since missing a dose at the normal time, the patient should not take the dose, but take the next dose at the normal time on the following day.

Posology

Newly diagnosed multiple myeloma (NDMM)

- Lenalidomide maintenance in patients who have undergone autologous stem cell transplantation (ASCT)

Lenalidomide maintenance should be initiated after adequate haematologic recovery following ASCT in patients without evidence of progression. Lenalidomide must not be started if the Absolute Neutrophil Count (ANC) is < 1.0 x 109/L, and/or platelet counts are < 75 x 109/L.

Recommended dose

The recommended starting dose is lenalidomide 10 mg orally once daily continuously (on days 1 to 28 of repeated 28-day cycles) given until disease progression or intolerance. After 3 cycles of lenalidomide maintenance, the dose can be increased to 15 mg orally once daily if tolerated.

- Dose reduction steps

Starting dose (10 mg)

If dose increased (15 mg) a

Dose level -1

5 mg

10 mg

Dose level -2

5 mg (days 1-21 every 28 days)

5 mg

Dose level -3

Not applicable

5 mg (days 1-21 every 28 days)

Do not dose below 5 mg (days 1-21 every 28 days)

a After 3 cycles of lenalidomide maintenance, the dose can be increased to 15 mg orally once daily if tolerated.

- Thrombocytopenia

When platelets

Recommended course

Fall to < 30 x 109/L

Interrupt lenalidomide treatment

Return to > 30 x 109/L

Resume lenalidomide at dose level -1 once daily

For each subsequent drop below 30 x 109/L

Interrupt lenalidomide treatment

Return to > 30 x 109/L

Resume lenalidomide at next lower dose level once daily

- Neutropenia

When neutrophils

Recommended coursea

Fall to < 0.5 x 109/L

Interrupt lenalidomide treatment

Return to > 0.5 x 109/L

Resume lenalidomide at dose level -1 once daily

For each subsequent drop below < 0.5 x 109/L

Interrupt lenalidomide treatment

Return to > 0.5 x 109/L

Resume lenalidomide at next lower dose level once daily

a At the physician's discretion, if neutropenia is the only toxicity at any dose level, add granulocyte colony stimulating factor (G-CSF) and maintain the dose level of lenalidomide.

- Lenalidomide in combination with dexamethasone until disease progression in patients who are not eligible for transplant

Lenalidomide treatment must not be started if the ANC is < 1.0 x 109/L, and/or platelet counts are < 50 x 109/L.

Recommended dose

The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles.

The recommended dose of dexamethasone is 40 mg orally once daily on days 1, 8, 15 and 22 of repeated 28-day cycles. Patients may continue lenalidomide and dexamethasone therapy until disease progression or intolerance.

- Dose reduction steps

Lenalidomidea

Dexamethasonea

Starting dose

25 mg

40 mg

Dose level -1

20 mg

20 mg

Dose level -2

15 mg

12 mg

Dose level -3

10 mg

8 mg

Dose level- 4

5 mg

4 mg

Dose level -5

2.5 mg

Not applicable

a Dose reduction for both products can be managed independently

- Thrombocytopenia

When platelets

Recommended course

Fall to < 25 x 109/L

Stop lenalidomide dosing for remainder of cyclea

Return to > 50 x 109/L

Decrease by one dose level when dosing resumed at next cycle

a If Dose limiting toxicity (DLT) occurs on > day15 of a cycle, lenalidomide dosing will be interrupted for at least the remainder of the current 28- day cycle.

- Neutropenia

When neutrophils

Recommended course

First fall to < 0.5 x 109/L

Interrupt lenalidomide treatment

Return to > 1 x 109/L when neutropenia is the only observed toxicity

Resume lenalidomide at starting dose once daily

Return to > 0.5 x 109/L when dose-dependent haematological toxicities other than neutropenia are observed

Resume lenalidomide at dose level -1 once daily

For each subsequent drop below < 0.5 x 109/L

Interrupt lenalidomide treatment

Return to > 0.5 x 109/L

Resume lenalidomide at next lower dose level once daily.

For hematologic toxicity the dose of lenalidomide may be re-introduced to the next higher dose level (up to the starting dose) upon improvement in bone marrow function (no hematologic toxicity for at least 2 consecutive cycles: ANC >1,5 x 109/L with a platelet count > 100 x 109/L at the beginning of a new cycle).

- Lenalidomide in combination with melphalan and prednisone followed by lenalidomide maintenance in patients who are not eligible for transplant

Lenalidomide treatment must not be started if the ANC is < 1.5 x 109/L, and/or platelet counts are < 75 x 109/L.

Recommended dose

The recommended starting dose is lenalidomide 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 1 to 4 of repeated 28-day cycles, prednisone 2 mg/kg orally on days 1 to 4 of repeated 28-day cycles. Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide monotherapy as follows: 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles given until disease progression.

- Dose reduction steps

Lenalidomide

Melphalan

Prednisone

Starting dose

10 mga

0.18 mg/kg

2 mg/kg

Dose level -1

7.5 mg

0.14 mg/kg

1 mg/kg

Dose level -2

5 mg

0.10 mg/kg

0.5 mg/kg

Dose level -3

2.5 mg

Not applicable

0.25 mg/kg

a If neutropenia is the only toxicity at any dose level, add granulocyte colony stimulating factor (G-CSF) and maintain the dose level of lenalidomide

- Thrombocytopenia

When platelets

Recommended course

First fall to < 25 x 109/L

Interrupt lenalidomide treatment

Return to > 25 x 109/L

Resume lenalidomide and melphalan at dose level -1

For each subsequent drop below 30 x 109/L

Interrupt lenalidomide treatment

Return to > 30 x 109/L

Resume lenalidomide at next lower dose level (dose level -2 or -3) once daily.

- Neutropenia

When neutrophils

Recommended course

First fall to < 0.5 x 109/La

Interrupt lenalidomide treatment

Return to > 0.5 x 109/L when neutropenia is the only observed toxicity

Resume lenalidomide at starting dose once daily

Return to > 0.5 x 109/L when dose-dependent haematological toxicities other than neutropenia are observed

Resume lenalidomide at dose level -1 once daily

For each subsequent drop below < 0.5 x 109/L

Interrupt lenalidomide treatment

Return to > 0.5 x 109/L

Resume lenalidomide at next lower dose level once daily.

aIf the subject has not been receiving G-CSF therapy, initiate G-CSF therapy. On day 1 of next cycle, continue G-CSF as needed and maintain dose of lenalidomide if neutropenia was the only DLT. Otherwise, decrease by one dose level at start of next cycle.

Multiple myeloma with at least one prior therapy

Lenalidomide treatment must not be started if the ANC < 1.0 x 109/L, and/or platelet counts < 75 x 109/L or, dependent on bone marrow infiltration by plasma cells, platelet counts < 30 x 109/L.

Recommended dose

The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 1 to 4 every 28 days.

Prescribing physicians should carefully evaluate which dose of dexamethasone to use, taking into account the condition and disease status of the patient.

- Dose reduction steps

Starting dose

25 mg

Dose level -1

15 mg

Dose level -2

10 mg

Dose level -3

5 mg

- Thrombocytopenia

When platelets

Recommended course

First fall to < 30 x 109/L

Interrupt lenalidomide treatment

Return to > 30 x 109/L

Resume lenalidomide at dose level -1

For each subsequent drop below 30 x 109/L

Interrupt lenalidomide treatment

Return to > 30 x 109/L

Resume lenalidomide at next lower dose level (dose level -2 or -3) once daily. Do not dose below 5 mg once daily.

- Neutropenia

When neutrophils

Recommended course

First fall to < 0.5 x 109/L

Interrupt lenalidomide treatment

Return to > 0.5 x 109/L when neutropenia is the only observed toxicity

Resume lenalidomide at starting dose once daily

Return to > 0.5 x 109/L when dose-dependent haematological toxicities other than neutropenia are observed

Resume lenalidomide at dose level -1 once daily

For each subsequent drop below < 0.5 x 109/L

Interrupt lenalidomide treatment

Return to > 0.5 x 109/L

Resume lenalidomide at next lower dose level (dose level -1, -2 or -3) once daily. Do not dose below 5 mg once daily.

Myelodysplastic syndromes (MDS)

Lenalidomide treatment must not be started if the ANC < 0.5 x 109/L and/or platelet counts < 25 x 109/L.

Recommended dose

The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles.

- Dose reduction steps

Starting dose

10 mg once daily on days 1 to 21 every 28 days

Dose level -1

5 mg once daily on days 1 to 28 every 28 days

Dose level -2

2.5 mg once daily on days 1 to 28 every 28 days

Dose level -3

2.5 mg every other day 1 to 28 every 28 days

- Thrombocytopenia

When platelets

Recommended course

Fall to < 25 x 109/L

Interrupt lenalidomide treatment

Return to > 25 x 109/L - < 50 x 109/L on at least 2 occasions for > 7 days or when the platelet count recovers to > 50 x 109/L at any time

Resume lenalidomide at next lower dose level (dose level -1, -2 or -3)

- Neutropenia

When neutrophils

Recommended course

Fall to < 0.5 x 109/L

Interrupt lenalidomide treatment

Return to > 0.5 x 109/L

Resume lenalidomide at next lower dose level (dose level -1, -2 or -3)

Discontinuation of lenalidomide

Patients without at least a minor erythroid response within 4 months of therapy initiation, demonstrated by at least a 50% reduction in transfusion requirements or, if not transfused, a 1g/dl rise in haemoglobin, should discontinue lenalidomide treatment.

Mantle cell lymphoma (MCL)

Recommended dose

The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles.

- Dose reduction steps

Starting dose

25 mg once daily on days 1 to 21, every 28 days

Dose Level -1

20 mg once daily on days 1 to 21, every 28 days

Dose Level -2

15 mg once daily on days 1 to 21, every 28 days

Dose Level -3

10 mg once daily on days 1 to 21, every 28 days

Dose Level -4

5 mg once daily on days 1 to 21, every 28 days

Dose Level -5

2.5 mg once daily on days 1 to 21, every 28 days1

5 mg every other day on days 1 to 21, every 28 days

1 - In countries where the 2.5 mg capsule is available.

- Thrombocytopenia

When platelets

Recommended Course

Fall to < 50 x 109/L

Interrupt lenalidomide treatment and conduct Complete Blood Count (CBC) at least every 7 days

Return to > 60 x 109/L

Resume lenalidomide at next lower level (dose level -1)

For each subsequent drop below 50 x 109/L

Interrupt lenalidomide treatment and conduct the CBC at least every 7 days

Return to >60 x 109/L

Resume lenalidomide at next lower level (dose level -2, -3, -4 or -5). Do not dose below dose level -5

- Neutropenia

When neutrophils

Recommended Course

Fall to < 1 x 109/L for at least 7 days or

Falls to < 1 x 109/L with associated fever (body temperature > 38.5°C) or

Falls to < 0.5 x 109/L

Interrupt lenalidomide treatment and conduct the CBC at least every 7 days

Return to > 1 x 109/L

Resume lenalidomide at next lower dose level (dose level -1)

For each subsequent drop below 1 x 109/L for at least 7 days or drop to < 1 x 109/L with associated fever (body temperature > 38.5°C) or drop to < 0.5 x 109/L

Interrupt lenalidomide treatment

Returns to >1 x 109/L

Resume Lenalidomide at next lower dose level (dose level -2, -3, -4, -5). Do not dose below dose level -5

Tumour flare reaction

Lenalidomide may be continued in patients with Grade 1 or 2 tumour flare reaction (TFR) without interruption or modification, at the physician's discretion. In patients with Grade 3 or 4 TFR, withhold treatment with lenalidomide until TFR resolves to ≤ Grade 1 and patients may be treated for management of symptoms per the guidance for treatment of Grade 1 and 2 TFR.

All indications

For other grade 3 or 4 toxicities judged to be related to lenalidomide, treatment should be stopped and only restarted at next lower dose level when toxicity has resolved to ≤ grade 2 depending on the physician's discretion.

Lenalidomide interruption or discontinuation should be considered for grade 2 or 3 skin rash. Lenalidomide must be discontinued for angioedema, grade 4 rash, exfoliative or bullous rash, or if Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is suspected, and should not be resumed following discontinuation from these reactions.

Special populations

- Paediatric population

Lenalidomide should not be used in children and adolescents from birth to less than 18 years because of safety concerns.

- Elderly

Lenalidomide has been used in clinical trials in multiple myeloma patients up to 91 years of age, in myelodysplastic syndromes patients up to 95 years of age and in mantle cell lymphoma patients up to 88 years of age.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it would be prudent to monitor renal function.

Newly diagnosed multiple myeloma: patients who are not eligible for transplant

Patients with newly diagnosed multiple myeloma aged 75 years and older should be carefully assessed before treatment is considered.

For patients older than 75 years of age treated with lenalidomide in combination with dexamethasone, the starting dose of dexamethasone is 20 mg once daily on days 1, 8, 15 and 22 of each 28-day treatment cycle.

No dose adjustment is proposed for patients older than 75 years who are treated with lenalidomide in combination with melphalan and prednisone.

In patients with newly diagnosed multiple myeloma aged 75 years and older who received lenalidomide, there was a higher incidence of serious adverse reactions and adverse reactions that led to treatment discontinuation.

Lenalidomide combined therapy was less tolerated in newly diagnosed multiple myeloma patients older than 75 years of age compared to the younger population. These patients discontinued at a higher rate due to intolerance (Grade 3 or 4 adverse events and serious adverse events), when compared to patients < 75 years.

Multiple myeloma: patients with at least one prior therapy

The percentage of multiple myeloma patients aged 65 or over was not significantly different between the lenalidomide/dexamethasone and placebo/dexamethasone groups. No overall difference in safety or efficacy was observed between these patients and younger patients, but greater pre-disposition of older individuals cannot be ruled out.

Myelodysplastic syndromes

For myelodysplastic syndromes patients treated with lenalidomide, no overall difference in safety and efficacy was observed between patients aged over 65 and younger patients.

Mantle cell lymphoma

For mantle cell lymphoma patients treated with lenalidomide, no overall difference in safety and efficacy was observed between patients aged 65 years or over compared with patients aged under 65 years of age.

- Patients with renal impairment

Lenalidomide is primarily excreted by the kidney; patients with greater degrees of renal impairment can have impaired treatment tolerance. Care should be taken in dose selection and monitoring of renal function is advised.

No dose adjustments are required for patients with mild renal impairment and multiple myeloma, myelodysplastic syndromes or mantle cell lymphoma.

The following dose adjustments are recommended at the start of therapy and throughout treatment for patients with moderate or severe impaired renal function or end stage renal disease.

There are no phase III trial experiences with End Stage Renal Disease (ESRD) (CLcr < 30 mL/min, requiring dialysis).

Multiple myeloma

Renal function (CLcr)

Dose adjustment

(days 1 to 21 of repeated 28-day cycles)

Moderate renal impairment

(30 ≤ CLcr < 50 mL/min)

10 mg once daily1

Severe renal impairment

(CLcr < 30 mL/min, not requiring dialysis)

7.5 mg once daily2

15 mg every other day

End Stage Renal Disease (ESRD)

(CLcr < 30 mL/min, requiring dialysis)

5 mg once daily. On dialysis days, the dose should be administered following dialysis.

1 The dose may be escalated to 15 mg once daily after 2 cycles if patient is not responding to treatment and is tolerating the treatment.

2 In countries where the 7.5 mg capsule is available.

Myelodysplastic syndromes

Renal function (CLcr)

Dose adjustment

Moderate renal impairment

(30 ≤ CLcr < 50 mL/min)

Starting dose

5 mg once daily

(days 1 to 21 of repeated 28-day cycles)

Dose level -1*

2.5 mg once daily

(days 1 to 28 of repeated 28-day cycles)

Dose level -2*

2.5 mg once every other day

(days 1 to 28 of repeated 28-day cycles)

Severe renal impairment

(CLcr < 30 mL/min, not requiring dialysis)

Starting dose

2.5 mg once daily

(days 1 to 21 of repeated 28-day cycles)

Dose level -1*

2.5 mg every other day

(days 1 to 28 of repeated 28-day cycles)

Dose level -2*

2.5 mg twice a week

(days 1 to 28 of repeated 28-day cycles)

End Stage Renal Disease (ESRD)

(CLcr < 30 mL/min, requiring dialysis)

On dialysis days, the dose should be administered following dialysis.

Starting dose

2.5 mg once daily

(days 1 to 21 of repeated 28-day cycles)

Dose level -1*

2.5 mg every other day

(days 1 to 28 of repeated 28-day cycles)

Dose level -2*

2.5 mg twice a week

(days 1 to 28 of repeated 28-day cycles)

* Recommended dose reduction steps during treatment and restart of treatment to manage grade 3 or 4 neutropenia or thrombocytopenia, or other grade 3 or 4 toxicity judged to be related to lenalidomide, as described above.

Mantle cell lymphoma

Renal function (CLcr)

Dose adjustment

(days 1 to 21 of repeated 28-day cycles)

Moderate renal impairment

(30 ≤ CLcr < 50 mL/min)

10 mg once daily1

Severe renal impairment

(CLcr < 30 mL/min, not requiring dialysis)

7.5 mg once daily2

15 mg every other day

End Stage Rena

Special precautions for disposal and other handling

Capsules should not be opened or crushed. If powder from lenalidomide makes contact with the skin, the skin should be washed immediately and thoroughly with soap and water. If lenalidomide makes contact with the mucous membranes, they should be thoroughly flushed with water.

Any unused product or waste material should be returned to the pharmacist for safe disposal in accordance with local requirements.